Jasmine Anish
Nurse Practitioner · Glen Ellyn, ILNPI 1558959262
Payments from drug & device makers
Across 371 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Corcept Therapeutics$541
- Bayer$407
- Novo Nordisk$390
- Xeris Pharmaceuticals, Inc.$292
- Mannkind Corporation$266
- plus $4K from 35 others
What the payments were for
- Food & beverage$7,38199%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 112 | $1,991 |
| Corcept Therapeutics | 19 | $541 |
| Bayer | 16 | $407 |
| Novo Nordisk | 19 | $390 |
| Xeris Pharmaceuticals, Inc. | 14 | $292 |
| Mannkind Corporation | 12 | $266 |
| Boehringer Ingelheim | 11 | $263 |
| Tandem Diabetes Care, Inc. | 13 | $254 |
| AstraZeneca(2 entities) | 10 | $250 |
| Amneal Pharmaceuticals LLC | 14 | $249 |
| Ascensia Diabetes Care US Inc. | 11 | $234 |
| Amgen | 13 | $215 |
| Esperion Therapeutics, Inc. | 11 | $207 |
| Sanofi-aventis U.S. LLC | 9 | $191 |
| Ascendis Pharma Endocrinology Inc | 6 | $150 |
| Recordati_rare_diseases_inc. | 6 | $146 |
| Antares Pharma, Inc. | 8 | $142 |
| BETA Bionics, Inc. | 6 | $138 |
| Abbott | 11 | $136 |
| Kyowa Kirin, Inc. | 5 | $124 |
| IBSA Pharma Inc. | 6 | $93 |
| Halozyme Inc | 4 | $83 |
| Merck | 4 | $71 |
| Neurocrine Biosciences, Inc. | 2 | $68 |
| AbbVie | 4 | $63 |
| OPKO Pharmaceuticals, LLC | 3 | $55 |
| Embecta Corp. | 2 | $50 |
| Medtronic | 2 | $48 |
| Radius Health, Inc. | 3 | $47 |
| Insulet Corporation | 2 | $44 |
| Sequel Med Tech, LLC | 2 | $32 |
| Cequr Corporation | 2 | $29 |
| GSK | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| BD | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
How this compares
$7,448 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $97,189 |
| JardianceEmpagliflozin | 46 | $68,645 |
| TrulicityDulaglutide | 44 | $61,011 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $50,344 |
| MounjaroTirzepatide | 19 | $26,539 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,162 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 70 | $9,511 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $9,439 |
| Novolog FlexpenInsulin Aspart | 23 | $7,426 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $6,934 |
| Droplet Pen NeedlePen Needle, Diabetic | 11 | $1,294 |
| Levothyroxine Sodium | 106 | $1,113 |
| Rosuvastatin Calcium | 16 | $148 |
| Atorvastatin Calcium | 20 | $145 |
| Metformin Hcl | 23 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $390 | $97,18965 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,991 | $87,55063 claims |
| Boehringer IngelheimJardiance | $263 | $68,64546 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $249 | $1,113106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Glen Ellyn
- Erika VuckoChicago$417K
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Kristy LukeChicago$77K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
- Dara McKinleyEvanston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.